Recently, several studies have made encouraging discoveries in the metabolomics of asymptomatic FMR1 premutation carriers and FXTAS, which provide promising insight for the identification of potential biomarkers and therapeutic pathways. The gene discussed is FMR1; the disease is fragile X-associated tremor/ataxia syndrome.